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ABSTRACT 
Aims:  Trebananib, a peptide-Fc fusion protein, inhibits angiogenesis by inhibiting binding of 
angiopoietin-1/2 to the receptor tyrosine kinase Tie2.  This randomized, double-blind, placebo-
controlled phase 3 study evaluated whether trebananib plus pegylated liposomal doxorubicin 
(PLD) improved progression-free survival (PFS) in patients with recurrent epithelial ovarian 
cancer. 
Methods:  Women with recurrent ovarian cancer (platinum-free interval ≤12 months) were 
randomized to intravenous PLD 50 mg/m2 once every 4 weeks plus weekly intravenous 
trebananib 15 mg/kg or placebo.  PFS was the primary endpoint; key secondary endpoints were 
objective response rate (ORR) and duration of response (DOR).  Owing to PLD shortages, 
enrollment was paused for 13 months; the study was subsequently truncated.  
Results:  Two hundred twenty-three patients were enrolled.  Median PFS was 7.6 months 
(95%CI, 7.2─9.0) in the trebananib arm and 7.2 months (95%CI, 4.8─8.2) in the placebo arm, 
with a hazard ratio of 0.92 (95%CI, 0.68─1.24).  However, because the proportional hazards 
assumption was not fulfilled, the standard Cox model did not provide a reliable estimate of the 
hazard ratio.  ORR in the trebananib arm was 46% versus 21% in the placebo arm (odds ratio, 
3.43; 95%CI, 1.78‒6.64). Median DOR was improved (trebananib, 7.4 [95%CI, 5.7‒7.6] months; 
placebo, 3.9 [95%CI, 2.3‒6.5] months).  Adverse events with a greater incidence in the 
trebananib arm included localized edema (61% versus 32%), ascites (29% versus 9%), and 
vomiting (45% versus 33%).  
Conclusions:  Trebananib demonstrated anticancer activity in this phase 3 study, indicated by 
improved ORR and DOR.  Median PFS was not improved.  No new safety signals were 
identified. 
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HIGHLIGHTS 
 Trebananib + PLD did not meet the primary endpoint of improving PFS 
 However, trebananib + PLD improved objective response rate and duration of response 
 No new safety signals were identified in the ENGOT-ov-6/TRINOVA-2 study 
 
Key Words:  ENGOT-ov-6/TRINOVA-2, trebananib, pegylated liposomal doxorubicin, 
progression-free survival, objective response rate, duration of response 
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INTRODUCTION 
First-line platinum/taxane therapy is effective in the treatment of ovarian cancer [1].  
However, the risk of recurrence is high, and outcomes for these patients are poor [2,3].  For 
patients with recurrence following first-line platinum-based therapy, pegylated liposomal 
doxorubicin (PLD) represents an effective nonplatinum second-line therapy [4-8].  All patients 
will experience disease progression, underscoring the need to improve outcomes. 
Angiogenesis is a multifactorial process that plays a key role in tumor growth, 
development, and metastasis [2].  Two distinct pathways are important regulators of 
angiogenesis:  the VEGF pathway and the angiopoietin-Tie2 receptor axis [9-11].  Agents 
targeting the VEGF pathway have been shown to improve progression-free survival (PFS) in 
patients with ovarian cancer but have not been shown to prolong overall survival (OS) [12-20].  
Preclinical studies support the angiopoietin pathway as an important target in ovarian cancer 
[11].  Angiopoietin-1 and angiopoietin-2 regulate angiogenesis and vascular remodeling both in 
normal ovarian physiology and in tumors [11]. 
Trebananib (AMG 386) is a peptide-Fc fusion protein that binds angiopoietin-1 and 
angiopoietin-2, preventing their interaction with the Tie2 receptor [21,22].  In a phase 1b study, 
trebananib plus either PLD or topotecan was tolerable in patients with recurrent ovarian cancer, 
with evidence of antitumor activity [23].  Trebananib combined with weekly paclitaxel has shown 
antitumor activity in women with recurrent ovarian cancer [24,25].  The primary objective of the 
phase 3 Trebananib in Ovarian Cancer-2 (TRINOVA-2) study was to evaluate PFS in patients 
with platinum-resistant or partially platinum-sensitive (platinum-free interval [PFI] ≤12 months) 
recurrent ovarian cancer receiving PLD in combination with trebananib or placebo. 
Marth et al  Page 5 of 37 
METHODS 
Patients 
Eligible patients had epithelial ovarian, peritoneal, or fallopian tube cancer with 
radiographic evidence of disease progression on or following their last dose of prior 
chemotherapy (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 [26]), 
had received one prior platinum-based chemotherapeutic regimen for management of primary 
disease with a PFI ≤12 months, and could have received ≤2 additional cytotoxic regimens for 
recurrent/persistent disease.  Patients were excluded if they had an ECOG performance status 
≥2; previously received PLD or anthracycline/mitoxantrone-based chemotherapy; received 
trebananib or another inhibitor of angiopoietins/Tie2; received radiotherapy within 14 days; 
previous abdominal/pelvic radiotherapy; arterial/venous thromboembolism or clinically 
significant cardiovascular disease within 12 months; clinically significant bleeding within 6 
months; CNS metastasis; nonhealing wound, ulcer, or fracture; higher-than-average risk of 
bowel perforation; or inadequate renal, hematologic, hepatic, or cardiovascular function.  The 
protocol was approved by each center’s independent ethics committee; patients provided 
written informed consent. 
Study Procedures 
This randomized, double-blind, phase 3 study was conducted at 69 sites in 16 countries, 
in collaboration with ENGOT (model C) [27].  Patients were randomized 1:1 to receive 
intravenous PLD 50 mg/m2 once every 4 weeks plus intravenous trebananib 15 mg/kg once 
weekly or intravenous placebo once weekly.  Randomization was stratified by PFI (≥0−≤6 
versus >6−≤12 months), measurable disease (presence/absence), and geographic region 
(North America versus Western Europe/Australasia versus rest of world).  Study treatment 
continued until disease progression, unacceptable toxicity, or withdrawal of consent.  If toxicity 
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occurred, dose modifications for PLD were permitted (to 40 mg/m2 and then 30 mg/m2 for 
palmar-plantar erythrodysesthesia or stomatitis; to 37.5 mg/m2 and then 25 mg/m2 for other 
toxicities).  Dose reductions for trebananib/placebo were not permitted. 
 The primary endpoint was PFS (time from randomization to radiographic disease 
progression per investigator by RECIST or death from any cause). Subjects not meeting these 
criteria at the analysis date were censored.  Key secondary endpoints were OS (time from 
randomization to death), objective response rate (ORR), change in tumor burden, duration of 
response, and incidence of adverse events (AEs). 
Enrollment began on April 18, 2011.  Due to a global shortage of PLD, enrollment in the 
study was suspended from November 23, 2011, to January 10, 2013.  On October 23, 2013, 
Amgen closed the study to patient screening, and the last patient was enrolled on November 12, 
2013.  In total, 223 patients were enrolled. 
Assessments 
Computed tomography or magnetic resonance imaging of at least the chest, abdomen, 
and pelvis was done before cycle 1 and every 8 weeks for the first 64 weeks after 
randomization, then every 16 weeks for 32 weeks, and every 24 weeks thereafter.  Response 
was assessed by investigators per RECIST version 1.1.  AEs occurring from start of treatment 
until the safety follow-up visit (30−37 days after last dose) were graded using the Common 
Terminology Criteria for Adverse Events, version 3.0 [28].  Health-related quality of life (HRQoL) 
was evaluated using Functional Assessment of Cancer Therapy–Ovary (FACT-O), FACT-O 
ovarian cancer subscale (OCS), EQ-5D or EQ-5D VAS [29,30]. 
Statistical Analysis 
Enrollment was initially planned for 380 patients.  At the time the study was closed to 
further enrollment, 223 patients had been enrolled.  After this truncation, the statistical analysis 
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plan was adjusted so that the primary analysis of PFS occurred after 170 patients had PFS 
events; the original methods of statistical analysis were maintained.  With 223 patients and 
assuming median PFS of 7.6 months for trebananib plus PLD and 5 months for placebo plus 
PLD (52% relative improvement; hazard ratio [HR], 0.66), the study had 80% statistical power to 
detect a reduction in the hazard of progression/death while limiting the overall one-sided type I 
error to 2.5%. 
PFS and OS (contingent on positive PFS outcome) were evaluated on an intent-to-treat 
basis.  ORR was evaluated for randomized patients with ≥1 measurable lesion.  Duration of 
response was evaluated in patients who had an objective response.  Safety analyses included 
patients who received ≥1 dose of trebananib/placebo or PLD and were summarized by 
treatment received. 
PFS and OS were evaluated using log-rank tests stratified by randomization factors.  A 
stratified Cox regression model was used to provide estimated HRs and two-sided 95% CIs.  
Nonproportionality of hazards between treatment groups was assessed by comparing the 
standardized Martingale residuals over time to normal distribution [31]; if this comparison was 
significant at the 5% level, a piecewise Cox model was used for analysis.  An exact Cochran-
Mantel-Haenszel test was used for analysis of ORR; the P value from this test was descriptive. 
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RESULTS 
Patient Demographics and Clinical Characteristics 
Two hundred twenty-three patients were randomized (trebananib, n=114; placebo, n=109; 
Figure 1).  The baseline characteristics were generally balanced across treatment arms with 
only minor variations (Table 1).  Median number of cycles of trebananib was 6.0 (range, 1─19); 
median number of cycles of placebo was 5.0 (range, 1─38).  Median number of cycles of PLD 
administered was 6.0 (interquartile range, 3─7; range, 1─19) in the trebananib arm and 4.0 
(interquartile range, 2─6; range, 1─18) in the placebo arm.  Median relative dose intensities for 
PLD were 87.7% and 90.3% in the trebananib and placebo treatment arms, respectively.  At the 
time of this analysis (cutoff date, August 29, 2014), 16 patients continued on treatment 
(trebananib, n=8; placebo, n=8). 
Progression-Free Survival 
After a median follow-up time of 12.4 months (interquartile range, 8.2‒15.5 months), 93 patients 
in the trebananib arm and 89 in the placebo arm had PFS events.  Trebananib did not 
significantly prolong PFS: median PFS for the intent-to-treat population was 7.6 months (95%CI, 
7.2─9.0) for trebananib and 7.2 months (95%CI, 4.8─8.2) for placebo (Figure 2A).  A Cox 
proportional hazards model yielded an HR of 0.92 (95%CI, 0.68‒1.24, P=0.57), but because the 
proportional hazards assumption was not fulfilled this model did not provide a reliable estimate 
of treatment effect.  Instead, a prespecified piecewise Cox model for PFS using 16-week 
intervals was used.  This piecewise model provided further evidence of the non-proportionality 
of hazards: HRs ranged from 0.59 from 0‒16 weeks to 2.38 at 64 weeks and later (Table 2).   
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Secondary Endpoints 
Trebananib plus PLD improved ORR compared with placebo plus PLD.  Among patients with 
measurable disease, 46/99 (46%) in the trebananib arm had an objective response versus 
20/94 (21%) in the placebo arm (odds ratio, 3.43; 95%CI, 1.78‒6.64; stratified Cochran-Mantel-
Haenszel test, P<0.001; Table 3).  Odds ratios for trebananib versus placebo arms were 
generally similar across subgroups, including those defined by the stratification factors (Figure 
3B).  Notably, the odds ratio more strongly favored the trebananib arm among patients with 
ascites at baseline (10.55; 95%CI, 2.26‒49.27) versus those without ascites at baseline (2.32; 
95%CI, 1.09‒4.94).  Among patients with an objective response, the median durations of 
response (95%CI) in the trebananib and placebo arms were 7.4 (5.7‒7.6) and 3.9 (2.3‒6.5) 
months, respectively (Figure 3A).  Overall, 78/99 patients in the trebananib arm and 63/94 
patients in the placebo arm had a decrease from baseline in the sum of the longest diameters of 
target lesions (Figure 3C). 
At the time of analysis, 104 patients (47%) had died.  In a descriptive analysis, median 
OS was 19.4 months (95%CI, 14.9‒22.6) in the trebananib arm and 17.0 months (95%CI, 12.9‒
24.4) in the placebo arm (HR, 0.94; 95%CI, 0.64‒1.39, Figure 2B).  Finally, trebananib 
treatment was not associated with a decrement in HRQoL when compared to placebo 
(Supplemental Figure 1).   
Adverse Events 
All patients who received ≥1 dose of study treatment (trebananib, n=113; placebo, 
n=108) experienced ≥1 treatment-emergent AE.  The incidence of AEs of grade ≥3 was 77% 
versus 72% among those who received trebananib and placebo, respectively.  The incidence of 
fatal AEs was 6% in the trebananib arm and 7% in the placebo arm.  Two patients in each arm 
had fatal AEs considered possibly related to trebananib/placebo (trebananib:  cerebral ischemia, 
right ventricular failure; placebo:  pulmonary embolism, respiratory failure).  AEs leading to 
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discontinuation of trebananib/placebo occurred in 27% of patients who received trebananib and 
21% of patients who received placebo.  AEs leading to discontinuation of PLD occurred in 18% 
of patients who received trebananib and 23% of patients who received placebo. 
AEs with a greater incidence in the trebananib arm included localized edema (61% 
versus 32%), as well as ascites (29% versus 9%), vomiting (45% versus 33%), hypokalemia 
(21% versus 10%), fatigue (53% versus 44%), and cough (20% versus 15%) (Table 4).  
Mucosal inflammation (18% versus 24%), abdominal pain (31% versus 38%), and neutropenia 
(13% versus 20%) occurred with greater incidence among patients who received placebo.  
Grade 3 edema events occurred in five patients who received trebananib and two patients who 
received placebo; there were no grade ≥4 edema events.  Seven patients discontinued 
treatment due to edema (trebananib, n=5; placebo, n=2).  Blurred vision occurred in 5% of 
patients who received trebananib and 3% of patients who received placebo.  AEs previously 
associated with anti-VEGF antiangiogenic agents [32] did not occur with greater incidence 
among patients who received trebananib versus placebo; these included hypertension 
(trebananib, 11% versus placebo, 8%), arterial thrombotic events (1% in both patient groups), 
proteinuria (5% versus 4%), impaired wound healing (2% versus 7%), gastrointestinal 
perforations (1% versus 0%), and venous thromboembolic events (11% versus 8%). 
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DISCUSSION 
Trebananib in combination with weekly paclitaxel has previously been shown to 
significantly improve PFS compared with placebo plus paclitaxel in women with recurrent 
ovarian cancer [25].  Consistent with this evidence, we found that trebananib plus PLD 
demonstrated anticancer activity, as shown by clinically meaningful improvements in ORR (46% 
versus 21%) and duration of response (7.4 months versus 3.9 months) for patients who 
received trebananib.   
Despite this evidence of antitumor activity the planned statistical analysis did not reveal 
an improved PFS in the trebananib plus PLD arm versus the placebo plus PLD arm (the primary 
endpoint was not met).  A requirement for the estimation of HRs using Cox models is that the 
risks of progression must remain proportional over time.  However, this assumption was not 
met, and the planned method of analysis could not yield a reliable estimate of the treatment 
effect.  Because the overall Cox model was thus not an appropriate method of analysis, we 
used a prespecified piecewise Cox model to evaluate PFS at 16-week intervals.  Although there 
appeared to be a risk reduction in patients in the trebananib arm during the initial phase of the 
study, this treatment effect was not maintained after 16 weeks.  Certain aspects of study 
conduct may have contributed to these results.   Enrollment was temporarily halted for 14 
months because of shortage of PLD.  This enrollment hold resulted in two time-separated study 
cohorts, with different median actual follow-up times.  Additionally, there were marked 
differences in exposure to PLD within treatment arms that were not anticipated before the study 
began.  Continuation of PLD beyond six cycles of treatment (the minimum number of planned 
treatment cycles) was at the discretion of the investigator.  Notably, a considerable proportion of 
patients received longer exposure to PLD (>6 cycles).  This broad range of treatment intensity 
with PLD within each treatment arm made comparisons between the arms challenging.  
Together, these study-related factors may have affected the proportionality of risk of progression 
Marth et al  Page 12 of 37 
over time and obscured any treatment effect on PFS.  Notably, ORR—which is not a time-to-
event endpoint and therefore may not have been confounded to the same extent as PFS—was 
46% in the trebananib arm versus 21% in the placebo arm.  Although the original enrollment 
target was not met, it appears unlikely that lack of statistical power was a primary driver for the 
failure to meet the primary endpoint.   
The addition of trebananib to PLD did not result in an increase in the incidence of grade 
≥3 AEs; no new safety signals associated with trebananib treatment were identified.  As 
reported in other studies [25], edema events (in particular localized edema) occurred more 
frequently among patients who received trebananib; however, few patients (4%) had grade 3 
edema and few discontinued owing to edema.  The combination of trebananib and PLD did not 
result in exacerbation of toxicities associated with PLD (eg, palmar-plantar erythrodysesthesia). 
Our results show that trebananib has incremental antitumor activity in combination with 
PLD, in terms of ORR and DOR, a finding that is consistent with previous studies that have 
demonstrated clinical activity of antiangiogenic agents in women with recurrent ovarian cancer.  
Combining anti-VEGF agents with chemotherapy has shown activity in this setting, although 
demonstrating robust improvements in outcomes has been challenging [12,13,19,33].  In the 
AURELIA trial, median PFS was significantly improved in the bevacizumab plus PLD group, 
whereas ORR and OS were not [34].   In the OCEANS study, addition of bevacizumab to 
chemotherapy improved PFS and ORR, but not OS [13,20].  In the ICON6 phase 3 trial, the 
combination of cediranib with platinum-based chemotherapy significantly improved PFS but OS 
was not significantly improved; notably there was evidence of nonproportional hazards [19].  
Finally, in the MITO-11 phase 2 clinical trial pazopanib plus weekly paclitaxel improved PFS 
versus paclitaxel alone without significantly prolonging OS [33].  Our results are also consistent 
with those that have previously demonstrated activity of trebananib in ovarian cancer.  
Trebananib plus weekly paclitaxel has previously been shown to improve PFS and ORR (but not 
OS) compared with placebo plus paclitaxel in patients with recurrent ovarian cancer in the 
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TRINOVA-1 study [24,25].  Duration of response, an endpoint that is independent of the time of 
treatment initiation, was longer in the trebananib arm both in this study and in the TRINOVA-1 
study (unpublished observation, 7.1 months [95%CI, 5.6‒8.2] for trebananib versus 5.1 months 
[95%CI, 3.8‒5.6] for placebo).  Interestingly, we found that the odds ratio for response 
(trebananib:placebo) was higher among patients with ascites at baseline compared with those 
without ascites at baseline.  This finding is consistent with subgroup analysis of the TRINOVA-1 
study  [35] and with analysis of studies evaluating bevacizumab in ovarian cancer [36-38].  
Together, these results suggest that patients with ascites may have disease that is particularly 
susceptible to treatment with antiangiogenic agents [39,40].   
In summary, although this study did not meet its primary endpoint of prolongation of 
PFS, trebananib added to PLD improved ORR and duration of response [25].  No new safety 
signals were identified with the combination of trebananib plus PLD.  
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Table 1. Demographics and Baseline Clinical Characteristics 
 
Trebananib Plus PLD 
n=114 
Placebo Plus PLD 
n=109 
Median (range) age, y 61 (53–68) 60 (53–66) 
Race/ethnicity, n (%) 
 White 
 Asian 
 Black  
 Other 
 
102 (89) 
10 (9) 
1 (1)  
1 (1) 
 
92 (84) 
12 (11) 
2 (2)  
3 (3) 
GOG performance status, n (%) 
 0 
 1 
 2 
 
75 (66) 
39 (34)  
0 (0) 
 
67 (62) 
41 (38)  
1 (1) 
Primary tumor type, n (%) 
 Ovarian cancer 
 Peritoneal carcinoma 
 Fallopian tube cancer 
 
98 (86) 
8 (7) 
8 (7) 
 
85 (87) 
13 (12) 
1 (1) 
Histologic type, n (%) 
 Serous 
 Endometrioid 
 Undifferentiated 
 Mucinous 
 Other 
 
89 (78) 
6 (5) 
3 (3)  
4 (4) 
12 (11) 
 
82 (75) 
7 (6) 
6 (6)  
1 (1) 
13 (12)  
Histologic grade, n (%) 
 Well differentiated 
 Moderately differentiated 
 Poorly differentiated 
 Unknown 
 
3 (3) 
14 (12) 
77 (68) 
20 (18) 
 
5 (5) 
18 (16) 
70 (64) 
16 (15) 
Prior lines of therapy, n (%) 
 1 
 2 
 3 
 
45 (40) 
45 (40) 
24 (21)  
 
40 (37) 
46 (42) 
23 (21)  
Platinum-free interval, n (%) 
 6 months 
 >6 to 12 months 
 
64 (56) 
50 (44) 
 
67 (62) 
42 (39) 
Prior antiangiogenic therapy, n (%) 20 (18) 16 (15) 
Measurable disease at baseline, n (%) 99 (87) 94 (86) 
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Region, n (%) 
 North America 
 Western Europe/Australasia 
 Rest of the world 
 
18 (16) 
76 (67) 
20 (18) 
 
14 (13) 
75 (69) 
20 (18) 
GOG=Gynecologic Oncology Group; IQR=interquartile range; PLD=pegylated liposomal 
doxorubicin. 
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Table 2.  Piecewise Cox Model for PFS Using 16-Week Intervals (Prespecified) 
Time Interval, Week HR* 95% CI Weight† P Value 
0–16 0.59 0.34–1.01 0.31 0.05 
16–32 1.07 0.60–1.92 0.27 0.81 
32–48 1.00 0.58–1.72 0.31 0.99 
48–64 1.55 0.56–4.29 0.09 0.40 
≥64 2.38 0.41–13.95 0.03 0.34 
HR=hazard ratio; PFS=progression-free survival. 
*HRs within each time interval are presented as trebananib group: placebo group; an HR <1.0 
indicates a lower average event rate and a longer time to event for the trebananib group relative 
to the placebo group. 
†Weight is inversely proportional to the variance of each interval estimate.  Values do not sum to 
1.00 due to rounding. 
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Table 3.  Objective Response Rates According to Treatment Arm  
 
Trebananib 
+ PLD 
(n=99) 
Placebo  
+ PLD 
(n=94) 
Objective response rate, % (95% CI) 46 (36–57) 21 (14–31) 
Best response assessment, n (%)   
 Complete response 1 (1) 2 (2) 
 Partial response 45 (46) 18 (19) 
 Stable disease 28 (28) 50 (53) 
 Progressive disease 14 (14) 16 (17) 
Unevaluable* 1 (1) 1(1) 
Not done† 10 (10) 7 (7) 
PLD=pegylated liposomal doxorubicin. 
*Patients for whom imaging was not performed at the scheduled assessment of response.  †Patients with a response assessment of 
complete response, partial response, or stable disease before scheduled first assessment of response without an additional 
assessment of a response.  
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Table 4.  Treatment-Emergent Adverse Events in 10% of Patients in Either Treatment Group 
 
Trebananib 
+ PLD 
(n=113) 
Placebo 
+ PLD 
(n=108) 
 Any Grade ≥3 Grade ≥4 Fatal Any Grade ≥3 Grade ≥4 Fatal 
All treatment-emergent adverse events, n (%) 113 (100) 87 (77) 15 (13) 7 (6) 108 (100) 78 (72) 21 (19) 7 (6) 
Treatment-emergent adverse events occurring 
in ≥10% of patients in either treatment arm, n 
(%) 
        
 Palmar-plantar erythrodysesthesia* 69 (61)  22 (20) 0 (0) 0 (0) 61 (57) 13 (12)  0 (0) 0 (0) 
 Localized edema* 69 (61) 5 (4) 0 (0) 0 (0) 34 (32)  2(2) 0 (0) 0 (0) 
 Nausea 67 (59) 7 (6) 0 (0) 0 (0) 62 (57) 5 (5) 0 (0) 0 (0) 
 Fatigue* 60 (53) 8 (7) 0 (0) 0 (0) 48 (44) 5 (5) 1 (1) 0 (0) 
 Stomatitis 58 (51) 7 (6) 1 (1) 0 (0) 55 (51) 6 (6) 0 (0) 0 (0) 
 Vomiting* 51 (45) 7 (6) 0 (0) 0 (0) 36 (33) 6 (6) 0 (0) 0 (0) 
 Abdominal pain* 35 (31) 7 (6) 0 (0) 0 (0) 41 (38) 5 (5) 0 (0) 0 (0) 
 Constipation 39 (34) 2 (2) 0 (0) 0 (0) 35 (32) 2 (2) 0 (0) 0 (0) 
 Diarrhea 33 (29) 3 (3) 1 (1) 1 (1) 28 (26) 5 (5) 0 (0) 0 (0) 
 Ascites* 33 (29) 24 (21) 0 (0) 0 (0) 10 (9) 7 (7) 0 (0) 0 (0) 
 Rash 31 (27) 2 (2) 0 (0) 0 (0) 28 (26) 2 (2) 0 (0) 0 (0) 
 Mucosal inflammation* 20 (18) 1 (1) 0 (0) 0 (0) 26 (24) 2 (2) 0 (0) 0 (0) 
 Decreased appetite 27 (24) 1 (1) 0 (0) 0 (0) 23 (21) 2 (2) 0 (0) 0 (0) 
 Dyspnea 24 (21) 5 (4) 0 (0) 0 (0) 18 (17) 3 (3) 2 (2) 1 (1) 
 Hypokalemia* 24 (21) 8 (7) 1( 1) 0 (0) 11 (10) 2 (2) 1 (1) 0 (0) 
 Cough* 23 (20) 0 (0) 0 (0) 0 (0) 16 (15) 0 (0) 0 (0) 0 (0) 
 Neutropenia* 15 (13)  8 (7) 1 (1) 0 (0) 22 (20) 13 (12) 4 (4) 0 (0) 
 Dyspepsia 21 (21) 1 (1) 0 (0) 0 (0) 16 (15) 0 (0) 0 (0) 0 (0) 
 Alopecia* 21 (19) 0 (0) 0 (0) 0 (0) 12 (11) 0 (0) 0 (0) 0 (0) 
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Trebananib 
+ PLD 
(n=113) 
Placebo 
+ PLD 
(n=108) 
 Any Grade ≥3 Grade ≥4 Fatal Any Grade ≥3 Grade ≥4 Fatal 
 Pyrexia 20 (18) 1 (1) 0 (0) 0 (0) 18 (17) 0 (0) 0 (0) 0 (0) 
 Back pain* 11 (10) 0 (0) 0 (0) 0 (0) 18 (17) 0 (0) 0 (0) 0 (0) 
 Abdominal pain, upper 17 (15) 0 (0) 0 (0) 0 (0) 17 (16)  2 (2) 0 (0) 0 (0) 
 Headache 15 (13) 3 (3) 0 (0) 0 (0) 16 (15) 1 (1) 0 (0) 0 (0) 
 Pleural effusion 16 (14) 6 (5) 0 (0) 0 (0) 11 (10) 4 (4) 1 (1) 1 (1) 
 Dizziness 12 (11) 0 (0) 0 (0) 0 (0) 15 (14) 1 (1) 0 (0) 0 (0) 
 Anemia 11 (10) 3 (3) 1 (1) 0 (0) 15 (14) 4 (4) 0 (0) 0 (0) 
 Oropharyngeal pain 15 (13) 0 (0) 0 (0) 0 (0) 10 (9) 0 (0) 0 (0) 0 (0) 
 Asthenia 9 (8) 0 (0) 0 (0) 0 (0) 13 (12) 3 (3) 0 (0) 0 (0) 
 Dry skin 9 (8) 0 (0) 0 (0) 0 (0) 13 (12) 0 (0) 0 (0) 0 (0) 
 Weight decreased* 4 (4) 0 (0) 0 (0) 0 (0) 12 (11) 2 (2) 0 (0) 0 (0) 
 Nasopharyngitis 12 (11) 0 (0) 0 (0) 0 (0) 11 (10) 0 (0) 0 (0) 0 (0) 
 Insomnia 11 (10) 0 (0) 0 (0) 0 (0) 11 (10) 1 (1) 0 (0) 0 (0) 
 Hypertension 12 (11) 3 (3) 0 (0) 0 (0) 9 (8) 0 (0) 0 (0) 0 (0) 
 Muscle spasms 9 (8) 0 (0) 0 (0) 0 (0) 11 (10) 0 (0) 0 (0) 0 (0) 
 Neuropathy, peripheral 8 (7) 0 (0) 0 (0) 0 (0) 11 (10) 0 (0) 0 (0) 0 (0) 
 Abdominal distension 7 (6) 0 (0) 0 (0) 0 (0) 11 (10) 2 (2) 0 (0) 0 (0) 
 Skin hyperpigmentation 7 (6) 0 (0) 0 (0) 0 (0) 11 (10) 0 (0) 0 (0) 0 (0) 
 Pain in extremity* 12 (11) 0 (0) 0 (0) 0 (0) 5 (5) 0 (0) 0 (0) 0 (0) 
 Pruritus 11 (10) 0 (0) 0 (0) 0 (0) 8 (7) 0 (0) 0 (0) 0 (0) 
 Upper respiratory tract infection 11 (10) 1 (1) 0 (0) 0 (0) 6 (6) 0 (0) 0 (0) 0 (0) 
 Hypomagnesaemia* 11 (10) 4 (4) 0 (0) 0 (0) 3 (3) 1 (1) 0 (0) 0 (0) 
PLD=pegylated liposomal doxorubicin. 
*Indicates a ≥5% difference in incidence between the trebananib plus PLD arm and the placebo plus PLD arm. 
Marth et al  Page 27 of 37 
FIGURES 
Figure 1. Disposition of patients in the study.  IV=intravenous; PLD=pegylated liposomal 
doxorubicin; QW=once weekly. 
Figure 2. (A) Kaplan-Meier analysis of progression-free survival. (B)  Kaplan-Meier 
analysis of overall survival.  HR=hazard ratio; PFS=progression-free survival; 
OS=overall survival; PLD=pegylated liposomal doxorubicin.  
Figure 3. (A) Kaplan-Meier analysis of duration of response.  (B) Objective response in 
patient subgroups defined by baseline characteristics.  (C) Maximum change in 
tumor size from baseline to postbaseline nadir (measurable disease at baseline) 
in individual patients receiving PLD plus trebananib or PLD plus placebo. 
PLD=pegylated liposomal doxorubicin; SLD=sum of longest diameter.  
CR=complete response; PR=partial response; SD=stable disease; 
PD=progressive disease; NE=not evaluated.  *Number of patients with an 
objective response (complete or partial response per modified RECIST version 
1.1).  †Arrows indicates an inestimable confidence interval for the upper or lower 
bounds for the plot.   
Figure 1. 
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Figure 2 
A  Progression-Free Survival 
 
B  Overall Survival 
Marth et al  Page 30 of 37 
Figure 3A 
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Figure 3B  
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Figure 3C 
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Supplemental Figure 1.  Health-related quality of life among patients with ascites receiving 
paclitaxel plus placebo or trebananib plus placebo at week 1 (baseline) through week 25.  
Health-related quality of life was evaluated with (A) FACT-O, (B) OCS, (C) EQ-5D, and (D) EQ-
5D VAS scores over time. FACT-O, Functional Assessment of Cancer Therapy–Ovary; OCS, 
ovarian cancer–specific subscale; VAS, visual analogue scale; IQR, interquartile range. 
A.  FACT-O 
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B. OCS 
 
  
Marth et al  Page 36 of 37 
C. EQ-5D 
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D. EQ-5D VAS 
 
